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Abstract  
Loss of glutamatergic synapses is thought to be a key cellular pathology associated 
with neuropsychiatric disorders including schizophrenia (SCZ) and major depressive 
disorder (MDD). Genetic and cellular studies of SCZ and MDD using in vivo and in 
vitro systems have supported a key role for dysfunction of excitatory synapses in the 
pathophysiology of these disorders. Recent clinical studies have demonstrated that 
the estrogen, 17β-estradiol can ameliorate many of the symptoms experienced by 
patients. Yet, to date, our understanding of how 17β-estradiol exerted these beneficial 
effects is limited. In this study, we have tested the hypothesis that 17β-estradiol can 
restore dendritic spine number in a cellular model that recapitulates the loss of 
synapses associated with SCZ and MDD. Ectopic expression of wildtype, mutant or 
shRNA-mediated knockdown of Disrupted in Schizophrenia (DISC1) reduced dendritic 
spine density in primary cortical neurons. Acute or chronic treatment with 17β-estradiol 
increased spine density to control levels in neurons with altered DISC1 levels. In 
addition, 17β-estradiol reduced the extent to which ectopic wildtype and mutant DISC1 
aggregated. Furthermore, 17β-estradiol also caused the enrichment of synaptic 
proteins at synapses and increased the number of dendritic spines containing PSD-
95 or that overlapped with the pre-synaptic marker bassoon. Taken together, our data 
indicates that estrogens can restore lost excitatory synapses caused by altered DISC1 
expression, potentially through the trafficking of DISC1 and its interacting partners. 
These data highlight the possibility that estrogens exert their beneficial effects in SCZ 
and MDD in part by modulating dendritic spine number.  
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Introduction 
  
 Glutamatergic synapse dysfunction is thought to be a key cellular hallmark of a 
number of neuropsychiatric disorders including schizophrenia (SCZ) and major 
depressive disorder (MDD)1-4. In the mammalian forebrain, the majority of excitatory 
glutamatergic synapses occur on specialized structures known as dendritic spines, 
which protrude off and decorate the dendrite of pyramidal neurons4, 5. Dendritic spines 
house the post-synaptic density (PSD), where a number of key synaptic proteins 
involved in synaptic transmission and signaling are located4, 5. Post-mortem studies 
have also shown that there are reduced dendritic spine numbers in the brains of 
patients with SCZ and MDD2, 6-8. Consistent with this genetic studies have linked a 
number of genes encoding for synaptic proteins or for proteins that regulate synapse 
structure or function with neuropsychiatric disorders including SCZ and MDD1, 2, 4, 9-11. 
Therefore, it has been suggested that regulating synapse protein and dendritic spine 
number may be a viable therapeutic strategy in the treatment of SCZ and/or MDD6, 11, 
12.  
The disrupted-in-schizophrenia 1 (DISC1) gene has been implicated in the 
pathophysiology of SCZ and MDD13-17. The association of DISC1 with 
neuropsychiatric disorders was originally identified through analysis of a large Scottish 
family where a balanced chromosomal translocation, associated with psychiatric 
illness14. This translocation  is thought to lead either to a loss of DISC1 or the formation 
of a dominant-negative C-terminally truncated DISC1 protein13, 16. DISC1 is a scaffold 
protein that is enriched at synapses where it interacts with a number of different 
proteins13, 18. DISC1 has been described to regulate dendrite spine morphology, 
number and glutamatergic transmission13, 15. While the contribution of DISC1 to the 
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etiology of SCZ and MDD remains unclear and somewhat controversial19, 20, results 
from animal and cellular models have demonstrated that altering the expression levels 
of DISC1 protein results in a loss of dendritic spine density21-24, a result consistent with 
that seen in postmortem studies of patients with SCZ or MDD2, 4, 11. Truncation of the 
C-terminal has been used extensively to model DISC1 pathology in cellular and 
transgenic models. Animal models expressing C-terminal truncated DISC1 constructs 
have been reported to display reduced spine density in vivo as well as in vitro22, 23, 25, 
26. 
 The neurosteroid, 17β-estradiol, has been shown to be a potent 
neuromodulator, having positive effects on cognitive processes including learning and 
memory as well as mood27, 28. The effect of 17β-estradiol, the principal biologically 
active estrogen, on cognition is thought to be driven, in part, by activation of specific 
signaling pathways resulting in alternations in dendritic spine number and the 
trafficking of key synaptic proteins (reviewed in 13). Recently, clinical studies have 
shown that treatment with 17β-estradiol has beneficial effects for patients diagnosed 
with SCZ or MDD, when given as an adjunct treatment to ongoing antipsychotic or 
antidepressant therapies29-34. However, the molecular and cellular mechanisms by 
which 17β-estradiol exert these beneficial effects are currently unknown. One 
possibility is that 17β-estradiol exerts its beneficial effects via the modulation of 
glutamatergic synapses27, 35, 36. However, this has not been tested directly in a cellular 
model of disease.  
 In this study, we have tested the hypothesis that 17β-estradiol can restore the 
number of excitatory synapses in a cellular model that recapitulates the loss of 
synapses associated with SCZ and MDD. To this end, we have utilized a cellular model 
of neuropsychiatric disorders, in the form of manipulating the expression levels of 
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DISC1 to reduce dendritic spine density in primary neuronal cultures21, 23, 37. 
Specifically, we have exogenously expressed wildtype rodent DISC1 or a C-terminal 
truncation mutant of rodent DISC1, which lacks amino acids 598-854, thus mimicking 
the truncated mutation proposed to be generated by the balance translocation 
associated with SCZ and MDD, or have used an shRNA approach to knockdown 
DISC1 expression13, 21, 38.  Subsequently, we treated cells with 17β-estradiol for 30 
minutes (acute) or for 4 days (chronic) to explore whether this neurosteroid could 
modulate dendritic spine density and synaptic protein expression at synapses in a 
cellular model, recapitulating aspects of the pathophysiology associated with SCZ and 
MDD. A number of studies have suggested that the aggregation of DISC1 might be 
important for psychiatric disease. An original study identified high molecular weight 
insoluble aggregates of DISC1 in patients specifically diagnosed with major mental 
illness including SZZ and MDD39, 40. Thus, we also investigated whether 17β-estradiol 
altered mutant or wildtype DISC1 aggregates, and further examined the sub-cellular 
distribution of endogenous DISC1 and its synaptic interacting proteins following 
treatment. Our results demonstrate that treatment with 17β-estradiol is sufficient to 
restore dendritic spine deficits to basal levels, whilst concurrently reducing DISC1 
aggregates. Moreover, we go on to show that 17β-estradiol can modulate DISC1 
enrichment at synapses, as well as its interacting partner, kalirin-7, a Rac-GEF known 
to regulate spine density21. Critically, we find that chronic treatment with 17β-estradiol 
increases spine density as well as the number of spines containing PSD-95 and that 
show overlap with bassoon. Thus, these data suggest that the mechanism by which 
17β-estradiol is beneficial in the treatment of SCZ and MDD, may in part be driven by 
its ability to regulate excitatory glutamatergic synapses. 
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Methods 
Reagents 
 Antibodies used: GFP chicken polyclonal (ab13970; Abcam; 1:10,000); HA 
mouse monoclonal (clone 16B12; 901503; BioLegend; 1:500); kalirin rabbit polyclonal 
(07-122; Millipore; 1:500); PSD-95 mouse monoclonal (clone K28/43; 73-028; 
NeuroMab; 1:1000); PSD-95 guinea pig polyclonal (124014; Synaptic Systems; 
1:500); bassoon rabbit monoclonal (6897; Cell Signaling Technologies; 1:200); DISC1 
440 rabbit polyclonal (used at 1:250) has been previously described41, 42. The antigenic 
peptide was RTPHPEEEKSPLQVLQEWD, which is identical in human, mouse and 
rat. DISC1–440 consistently recognizes four major isoforms from rat brain lysates, 
including two bands at 130 kD and two around 100 kD41, 42. 17β-estradiol (E8875) was 
from Sigma. HA-DISC1WT (wildtype), HA-DISC1ΔCT (mutant) and shRNA against 
rodent DISC1 constructs were kind gifts from A. Sawa (Johns Hopkins University); 
generation and validation of these constructs have previously been described21, 38. 
Both wildtype and mutant DISC1 constructs were generated based on rodent 
sequences; DISC1ΔCT lacks the C-terminal amino acids 598-854, and mimics the 
breakpoint associated with the balance translocation of DISC138, 43. 
  
Neuronal culture and transfections 
 Cortical neuronal cultures, consisting of mixed sexes, were prepared from E18 
Sprague-Dawley rat embryos as described previously44. Animals were habituated for 
3 days before experimental procedures, which were carried out in accordance with the 
Home Office Animals (Scientific procedures) Act, United Kingdom, 1986. Cells were 
plated onto 18 mm glass coverslips (No 1.5; 0117580, Marienfeld-Superior GmbH & 
Co.), coated with poly-D-lysine (0.2mg/ml, Sigma), at a density of 3x105/well equal to 
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857/mm2. Neurons were cultured in feeding media: neurobasal medium (21103049) 
supplemented with 2% B27 (17504044), 0.5 mM glutamine (25030024) and 1% 
penicillin:streptomycin (15070063) (all reagents from Life technologies). Neuron 
cultures were maintained in presence of 200 µM D,L-amino-phosphonovalerate (D,L-
APV, ab120004, Abcam) beginning on DIV (days in vitro) 4 in order to maintain 
neuronal health for long-term culturing and to reduce cell death due to excessive Ca2+ 
cytotoxicity via over-active NMDA receptors44. We have previously shown that the 
presence or absence of APV in the culture media does not affect E2's ability to 
increase spine linear density45. Half media changes were performed twice weekly until 
desired age (DIV 23-25). The primary cortical neurons were transfected with eGFP at 
DIV 23 for 2 days, using Lipofectamine 2000 (11668027, Life Technologies)44. Briefly, 
4-6 µg of plasmid DNA was mixed with Lipofectamine 2000 and incubated for 4-12 
hours, before being replaced with fresh feeding media. Transfections were allowed to 
proceed for 2-5 days after which cells were used for pharmacological treatment or 
immunocytochemistry (ICC).  
 
Pharmacological treatments of neuron culture 
 Acute pharmacological treatments were performed in artificial cerebral spinal 
fluid (aCSF): (in mM) 125 NaCl, 2.5 KCL, 26.2 NaHCO3, 1 NaH2PO4, 11 glucose, 5 
HEPES, 2.5 CaCl2, 1.25 MgCl2, and 0.2 APV). 17β-estradiol was dissolved in DMSO 
at a concentration of 10 mM, serially diluted to a 10X working concentration in aCSF, 
and applied directly to neuronal cultures. Final concentration of solvent was < 0.01%; 
vehicle control was made up of solvent lacking compound, diluted as test compounds. 
Treatments were allowed to proceed for 30 minutes before being lysed for Western 
blotting or fixed for ICC. 
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Chronic pharmacological treatments were performed by adding 17β-estradiol 
directly into media. Treatment started on the day of transfection and continued ever 
day until day 4. Cells were fixed 24 hours after the final treatment on day 5. Samples 
were then processed for ICC. 
 
Immunocytochemistry (ICC) 
 Neurons were washed in PBS and then fixed in either 4% formaldehyde/4% 
sucrose PBS for 10 minutes at room temperature followed by incubation in methanol 
pre-chilled to -20°C for 10 minutes at 4°C, or only in methanol (-20°C) for 20 minutes 
at 4°C. Fixed neurons were then permeabilized and blocked simultaneously (2% 
Normal Goat Serum, 5425S, New England Biolabs and 0.1% Triton X-100) before 
incubation in primary antibodies overnight and subsequent incubation with secondary 
antibodies the following day44. In the green/magenta colour scheme, co-localization is 
indicated by white overlap.  
 
Quantitative Analysis of Spine Morphologies and Immunofluorescence 
 Confocal images of double-stained neurons were acquired with a Leica SP-5 
confocal microscope using a 63x oil-immersion objective (Leica, N.A. 1.4) as a z-
series, or with a Zeiss Axio Imager Z1, equipped with an ApoTome using a 63x oil-
immersion objective (Carl Zeiss, N.A. 1.4). Two-dimensional maximum projection 
reconstructions of images were generated and linear density calculated using 
ImageJ/Fiji (https://imagej.nih.gov/ij/)44. Morphometric analysis was performed on 
spines from two dendrites (secondary or tertiary branches), totaling 100 µm, from each 
neuron. Linear density and total gray value of each synaptic protein cluster was 
measured automatically using MetaMorph Software (Molecular Devices)44. Cultures 
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directly compared were stained simultaneously and imaged with the same acquisition 
parameters. For each condition, 10-16 neurons from at least 3 separate experiments 
were used. Experiments were carried out blind to condition and on sister cultures.  
 
Biochemistry cell fractionation 
 Crude synaptosome fractions were prepared from DIV 25 neurons following 
treatment with 17β-estradiol or vehicle for 30 minutes. Cells were lysed in 
homogenization buffer (320 mM sucrose; 5 mM Na4P2O7; 1 mM EDTA pH 8; and 10 
mM HEPES pH 7.4 + protease inhibitors) and subsequently passed through a 21 
gauge needle 15 times. Cell lysate was then centrifuged to remove the nuclear fraction 
and large cell organelles (P1 fraction) and yield the extranuclear fraction (S1). A 
portion of the S1 fraction was kept and the remaining was subjected to further 
fractionation by an additional spin. This yielded the cytosolic (S2) and crude 
synaptosome (P2) fractions; the P2 fraction was resuspended in homogenization 
buffer. Sample buffer was added to all samples, which were then denatured for 5 
minutes at 95°C and stored at -80°C until used further. All samples were subsequently 
separated by SDS-PAGE and analyzed by Western Blotting with kalirin, DISC1, PSD-
95 and β-actin antibodies. Quantification of bands was performed by measuring the 
integrated intensity of each band and normalizing to β-actin, for protein loading, using 
Image J. 
 
Statistical Analysis 
 All statistical analysis were performed using Prism (GraphPad Software). 
Differences in quantitative immunofluorescence, dendritic spine number were 
identified by Student's unpaired t-tests, or for comparisons between multiple 
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conditions the main effects and simple effects were probed by one-way or two-way 
ANOVAs with Tukey correction for multiple comparisons. Error bars represent 
standard errors of the mean (SEM).  
 
 
Results 
Exogenous expression of C-terminal DISC1 mutant causes loss of dendritic 
spines and aggregates within dendrites.  
 Disruption in glutamatergic transmission and abnormal dendritic spine 
morphology and number is a cellular phenotype shared across a number of 
neurodevelopmental and psychiatric disorders4, 13. Manipulation of DISC1 function 
either through expression of wildtype or a C-terminal truncation mutant has previously 
been shown to induced spine loss in vitro21, 23. Therefore, we overexpressed either 
HA-tagged full-length DISC1 (HA-DISC1) or a C-terminal truncated DISC1 mutant 
(HA-DISC1ΔCT) in DIV 24-26 primary neurons. As expected, neurons expressing HA-
DISC1 had a reduced linear spine density compared to control cells (Figure 1A & B). 
Neurons exogenously expressing HA-DISC1ΔCT also displayed reduced spine 
density compared to control (Spine linear density per 10 µm: one-way ANOVA; 
F(2,46)=21.54, p<0.001, η2=0.48; Tukey Post Hoc, ***, p<0.001; n = 12-17 cells per 
condition from 3 independent cultures; Supplementary Figure 1A & B). Recent 
studies have also indicated that the aggregation of DISC1 may be central to its 
dominant negative effects and thus, contribute its pathophysiological role39, 46, 47. In 
primary cortical neurons, endogenous DISC1 is localized in punctate structures along 
dendrites and within dendritic spines, indicating an enrichment at synapses 
(Supplementary Figure 2A). Consistent with previous reports, HA-DISC1 formed 
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large aggregates within dendrites. Interestingly, HA-DISC1ΔCT also accumulated 
along dendrites (Supplementary Figure 2B & C). Taken together, these data reveal 
that both DISC1 and DISC1ΔCT causes a reduction in dendritic spine density and 
accumulate in dendrites where they appear to form aggregates in primary cortical 
neurons.  
 
Modulation of Dendritic spine density by 17β-estradiol in neurons expressing 
wildtype or C-terminal truncated DISC1. 
 Previous studies have demonstrated that 17β-estradiol can increase dendritic 
spine density in cortical neurons45, 48. 17β-estradiol has been reported as having an 
inverse “U” shaped dose-dependent effect on dendritic spine density49. Therefore, we 
investigated at which dose 17β-estradiol effectively increased dendritic spine density. 
Cortical neurons expressing GFP were treated either with vehicle (control), or with 
concentrations of 17β-estradiol: 10 pM, 100 pM, 1 nM, 10 nM or 100 nM for 30 minutes. 
Analogous to previous studies, we observed an inverse “U” shaped dose-response, 
where 1 and 10 nM, but not 10, 100 pM or 100 nM, produced a significant increase in 
spine linear density after 30 minutes of treatment (Spine linear density per 10 µm: one-
way ANOVA; F(5,97)=17.51, p<0.001, η2=0.47; Tukey Post Hoc, **, p < 0.01, ***, p < 
0.001; n = 16-21 cells per condition from 4 independent cultures; Supplementary 
Figure 3). 
 We were next interested in understanding whether 17β-estradiol could 
modulate dendritic spine density in neurons recapitulating a disease relevant reduction 
in spine number. Therefore, we next asked whether acute treatment with 17β-estradiol 
could also restore dendritic spine density in neurons overexpressing HA-DISC1 or HA-
DISC1ΔCT. Under control conditions, 17β-estradiol increased spine density compared 
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to vehicle treatment (Figure 1A, left panel). In neurons expressing HA-DISC1, 
treatment with 17β-estradiol resulted in an increase in the number of spines (Figure 
1A, middle panel). Similarly, in neurons ectopically expressing HA-DISC1ΔCT, spine 
density was again increased following 17β-estradiol treatment (Figure 1A, right 
panel). Interestingly, spine linear density was similar to untreated control condition in 
both HA-DISC1 and HA-DISC1ΔCT expressing cells acutely exposed to 17β-estradiol, 
(Spine linear density per 10 µm: two-way ANOVA; F(2,111)=23.73, p<0.0001, 
ηp2=0.42; Tukey Post Hoc, *, p < 0.05, **, p < 0.01, ***, p < 0.001; n = 16-25 cells per 
condition from 5 independent cultures; Figure 1A & B). Collectively, these data 
demonstrate that 17β-estradiol is capable of modulating dendritic spine linear density 
to a level similar to control in neurons expressing either wildtype or mutant DISC1.  
  
Acute treatment with 17β-estradiol reduces aggregation of wildtype and mutant 
DISC1. 
 Recent work has suggested that DISC1 forms aggregates under physiological 
and pathological conditions34, 41, 42. The formation of aggregates has been proposed 
to contributes to DISC1’s cellular function and the cellular pathology associated with 
the altered expression of this protein39, 46, 47. Intriguingly, reducing DISC1 aggregation 
has been linked with a reduction in cellular pathology46, 50. However, whether DISC1 
aggregation is linked with the loss of dendritic spine density induced by 
overexpression, and whether modulating DISC1 aggregation could influence synaptic 
deficits is not known. As 17β-estradiol could restore aberrant spine density back to a 
level similar to basal conditions, we tested the hypothesis that it may also reduce the 
extent to which ectopic DISC1 aggregated. Under control conditions, both HA-DISC1 
and HA-DISC1ΔCT could be observed as large clusters within the dendrite (Figure 
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1C). However, after treatment with 17β-estradiol, both HA-DISC1 and HA-DISC1ΔCT 
clustering was reduced, with smaller and fewer clusters evident within dendrites (HA-
DISC1 cluster intensity: Student t-test (corrected for multiple comparisons); 
t(20)=2.87, p=0.0096, two-tailed, Cohen’s d = 1.28; HA-DISC1ΔCT cluster intensity: 
Student t-test (corrected for multiple comparisons); t(21)=4.169, p=0.0004, two-tailed, 
Cohen’s d = 1.96; n = 12-13 cells per condition from 3 independent cultures) Figure 
1C & D). Taken together, these data indicate that concurrent with the ability to increase 
dendritic spine density, 17β-estradiol reduces clustering of exogenous wildtype and 
mutant DISC1.  
 
Acute 17β-estradiol treatment restores spine loss induced by reduced DISC1 
expression. 
 To ensure that the effects observed above were not due to an artifact of 
overexpressing DISC1 constructs, we employed a second approach to alter DISC1 
function. Previous studies have demonstrated that long term shRNA-mediated 
knockdown of DISC1 results in a loss of dendritic spine linear density in both in vitro 
and in vivo systems21, 37. Thus, reducing DISC1 expression levels has been suggested 
to be an approach to induce a cellular phenotype relevant for neurodevelopmental and 
psychiatric disorders37. To this end, we utilized a previously validated shRNA construct 
for rat DISC121, 37, 38. The DISC1_shRNA construct was able to knockdown exogenous 
HA-tagged rodent DISC1 in hEK293 cells, confirming it specificity for the protein 
(Student t-test; t(10)=10.54, p=<0.0001, two-tailed, Cohen’s d = 3.6; Figure 2A + B). 
We next expressed DISC1_shRNA or control construct in primary cortical neurons for 
7 days; this resulted in a significant reduction of spine linear density by ~35% 
compared to untreated control (Figure 2C + D), consistent with previous studies37. 
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Treatment of control neurons with 10 nM 17β-estradiol increased spine density by 
~40% within 30 minutes (Figure 2C + D). Interestingly, treatment of expressing 
DISC1_shRNA neurons with 17β-estradiol was sufficient to restore linear spine 
density to a level similar to control levels (Spine linear density per 10 µm: two-way 
ANOVA; F(1,50)=27.21, p<0.0001, ηp2=0.46; Tukey Post Hoc; * = p < 0.05; *** = p < 
0.001; n = 12-15 cells per condition from 4 independent cultures; Figure 2C + D). 
These data demonstrate that 17β-estradiol is capable of modulating spine linear 
density in neurons with reduced DISC1 levels. 
 
Redistribution of DISC1 and kalirin-7 following acute 17β-estradiol treatment. 
 As our data indicated that 17β-estradiol could modulate the sub-cellular 
distribution of exogenous wildtype and mutant DISC1, we reasoned that it may also 
influence the distribution of endogenous DISC1 and its binding partners. Therefore, 
we evaluated whether acute exposure to 17β-estradiol could alter the sub-cellular 
localization of the DISC1/PSD-95/kalirin-7 signalosome. In support of this idea we 
have recently shown that 17β-estradiol causes the rapid redistribution of several 
synaptic proteins, including PSD-95, from dendrites into spines48. Importantly, the 
ability of DISC1 to regulate spinogenesis is thought to be mediated by its interactions 
with key synaptic proteins, including PSD-95 and kalirin-7 a Rac-GEF21. We first tested 
this by examining whether levels of DISC1/PSD-95/kalirin-7 were altered following 
treatment with 17β-estradiol. Western blotting of whole cell lysates of neurons treated 
with 17β-estradiol for 0 or 30 minutes, revealed no change in overall expression of 
DISC1 (130 and 100 kDa isoforms), kalirin-7 or PSD-95 (Figure 3A; ‘whole cell 
lysate’). Next, we examined the enrichment of these proteins in crude synaptosomal 
(P2) and cytosol (S2) fractions. This revealed that 17β-estradiol caused a loss of 
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DISC1 130 and 100 kDa isoforms specifically within the P2 fraction, with a concurrent 
increase in S2 fraction (Figure 3A & B). Conversely, following treatment with 17β-
estradiol, the enrichment of both kalirin-7 and PSD-95 in crude synaptosomal fractions 
(P2) was increased, but decreased in S2 fractions. (DISC1 130 kDa: two-way ANOVA; 
F(1,8)=24.14, p=0.0012, ηp2=0.75; Bonferroni Post Hoc, *, p < 0.05, **, p < 0.01; n = 3 
independent cultures; DISC1 100 kDa: two-way ANOVA; F(1,8)=5.67, p=0.0446, 
ηp2=0.17; Bonferroni Post Hoc, *, p < 0.05, **, p < 0.01; n = 3 independent cultures; 
PSD-95: two-way ANOVA; F(1,8)=8.361, p=0.0202, ηp2=0.51; Bonferroni Post Hoc, *, 
p < 0.05; n = 3 independent cultures; kalirin-7: two-way ANOVA; F(1,8)=9.509, 
p=0.015, ηp2=0.54; Bonferroni Post Hoc, *, p < 0.05; n = 3 independent cultures; 
Figure 3A & B). To demonstrate that DISC1 was being removed from post-synaptic 
compartments, we further examined the content of this protein within dendritic spines 
with or without treatment. As suggested by our biochemical data, assessment of 
endogenous DISC1 content within spines was significantly reduced following 
treatment with 17β-estradiol (Student t-test; t(9)=2.97, p=0.0156, two-tailed, Cohen’s 
d = 1.8; n = 223-337 spines from 5-6 cells per condition from 3 independent cultures); 
Figure 3C). This was further highlighted by line scans analysis across spines, as 
following 17β-estradiol treatment, the intensity of DISC1 staining within dendritic 
spines was reduced (Supplemental Figure 4A). Thus, these data indicate that 17β-
estradiol specifically removes DISC1 from dendritic spines into non-synaptic regions. 
We next sought to determine whether kalirin-7 and PSD-95 were being 
trafficked to the same location following 17β-estradiol treatment, by assessing the 
number of kalirin-7 and co-localized PSD-95/kalirin-7 puncta. Consistent with our 
previous data, we observed an increase in the density of PSD-95 puncta (Figure 3D), 
which we have previously shown to represent an increase of synaptic sites48. Similarly, 
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we found that treatment with 17β-estradiol resulted in an increase in total kalirin-7 
puncta (kalirin-7 puncta per 10 µm: two-way ANOVA; F(1,46)=4.7, p=0.035, ηp2=0.11; 
Tukey Post Hoc; ** = p < 0.01; n = 12-15 cells per condition from 3 independent 
cultures; Figure 3D). Under control conditions, 65% of kalirin-7 puncta were positive 
for PSD-95; a similar level of co-localization was also seen following treatment with 
17β-estradiol (Figure 3D). Consistent with these data, we found that kalirin-7 intensity 
within spines increases primarily following 17β-estradiol treatment (Figure 3E). The 
enrichment of kalirin-7 within spines following treatment could also be illustrated using 
line scan analysis across dendritic spines (Supplemental Figure 4B), consequently 
supporting our biochemical data in demonstrating that a subpopulation of kalirin-7 was 
being trafficked to synaptic regions following 17β-estradiol treatment. Taken together, 
these data demonstrate that 17β-estradiol induces a bi-directional trafficking of DISC1, 
kalirin-7 and PSD-95, with the former protein having a reduced synaptic enrichment, 
and the latter two proteins increasing in their synaptic localization. 
 
Chronic repeated treatment with 17β-estradiol reverses spine loss induced by 
mutant DISC1 expression. 
 We next were interested in understanding whether chronic, repeated exposure 
to 17β-estradiol could reverse spine loss in our cellular model. To test this, we 
transfected primary cortical neurons with HA-DISC1ΔCT and GFP or just GFP 
(control), and simultaneously treated cells with either vehicle or 10 nM 17β-estradiol 
every day for 4 days. Twenty-four hours after the final treatment (5 days after 
transfection), cells were fixed, and spine linear density assessed (Figure 4A). In 
control cells expressing just GFP, repeated exposure to 17β-estradiol produced a 27% 
increase in spine density. A comparison of vehicle treated control and HA-DISC1ΔCT 
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conditions revealed that mutant DISC expressing cells had 30% fewer spines 
compared to control neurons. However, repeated exposure to 17β-estradiol reversed 
this effect and increased spine density in HA-DISC1ΔCT by 30%. Linear density did 
not differ between control and HA-DISC1ΔCT expressing cells repeatedly exposed to 
17β-estradiol (Spine linear density per 10 µm: two-way ANOVA; F(1,46)=10.48, 
p=0.0022, ηp2=0.23; Tukey Post Hoc; * = p < 0.05; n = 12-13 cells per condition from 
3 independent cultures; Figure 4B + C). We further examined clustering of exogenous 
mutant DISC1. This revealed that HA-DISC1ΔCT was less aggregated in cells 
exposed repeatedly to 17β-estradiol (HA-DISC1ΔCT cluster intensity: Student t-test; 
t(23)=2.66, p=0.0141, two-tailed, Cohen’s d = 1.07; n = 12-13 cells per condition from 
3 independent cultures) Figure 4B, D & E). Taken together, these data provide 
evidence that chronic repeated treatment with 17β-estradiol reverses spine loss 
induced by mutant DISC1. 
 One limitation of assessing spine density is that not all spine form synapses. 
Therefore, we were interested in determining whether chronic, repeated treatment with 
17β-estradiol was also altering the number of spines with the potential to form 
synapses. To this end, we assessed the number of spines that contained PSD-95 or 
showed overlap with the pre-synaptic and active zone marker, bassoon. Regardless 
of condition or treatment, we found that approximately 77% of spines were positive for 
PSD-95 immunoreactive puncta. There was a 26% decrease in the number of spines 
positive for PSD-95 in HA-DISC1ΔCT expressing cells compared to vehicle treated 
control neurons (Figure 5A & B). Treatment with 17β-estradiol increased the number 
of in spines containing PSD-95 by 34% in control cells. In HA-DISC1ΔCT expressing 
neurons, treatment with 17β-estradiol increased the number of spines containing PSD-
95 by 41% compared to vehicle treated HA-DISC1ΔCT expressing cells (Spines 
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positive for PSD-95 density per 10 µm: two-way ANOVA; F(1,46)=9.775, p=0.0031, 
ηp2=0.21; No differences between groups by Tukey Post Hoc; n = 12-13 cells per 
condition from 3 independent cultures; Figure 5A & B). Next we assessed the number 
of spines that showed overlap for bassoon within the same sample set. Once more, 
we found no difference in the percentage of spines positive for overlap for bassoon 
regardless of condition or treatment; approximately 68% of spines overlapped with 
bassoon across all conditions. Examination of linear density revealed that cells 
expressing HA-DISC1ΔCT had 20% fewer spines that overlapped with bassoon 
compared to control neurons (Figure 5A & C). Repeated exposure to 17β-estradiol 
produced a 41% increase in the number of spines that overlapped with bassoon in 
compared to both vehicle treated control or HA-DISC1ΔCT expressing cells (Spine 
overlapping with bassoon density per 10 µm: two-way ANOVA; F(1,45)=25.44, 
p<0.0001, ηp2=0.56 Tukey Post Hoc; * = p < 0.05 ** = p < 0.01; n = 12-13 cells per 
condition from 3 independent cultures; Figure 5A & C). Finally, we assessed the 
number of spines that were positive for both PSD-95 and that overlapped with 
bassoon. Across conditions, 60% of spines were positive for PSD-95 and overlapped 
with bassoon. When we examined the number of spines positive for both synaptic 
proteins, cells expressing HA-DISC1ΔCT had 30% fewer spines positive for PSD-95 
and bassoon compared to vehicle treated control neurons (Figure 5A & C). Neurons 
repeated exposed to 17β-estradiol had a 50% increase in spines positive for PSD-95 
and that overlapped with bassoon compared to vehicle treated control or HA-
DISC1ΔCT expressing neurons (Spine positive for PSD-95 and overlapping with 
bassoon density per 10 µm: two-way ANOVA; F(1,46)=23.26, p<0.0001, ηp2=0.51 
Tukey Post Hoc; * = p < 0.05 ** = p < 0.01; n = 12-13 cells per condition from 3 
independent cultures; Figure 5A & D). Collectively, these data provide evidence that 
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chronic repeated exposure to 17β-estradiol is sufficient to increase the number of 
spines that contain the anatomical hallmarks of being able to form synapses in both 
control and mutant DISC1 expressing cells. Therefore, 17β-estradiol appears to be 
able to increase the number of excitatory synapses in a cellular model relevant for 
psychiatric disorders. 
 
  
Discussion 
In this study, we have tested the hypothesis that 17β-estradiol can restore 
excitatory synapses number in a cellular model that recapitulates the loss of synapses 
associated with SCZ and MDD. We show that in cortical neurons with reduced 
dendritic spine density produced by manipulating DISC1, acute treatment with 17β-
estradiol increased spine density to control levels. Treatment with 17β-estradiol was 
also able to reduce the extent to which ectopic wildtype and mutant DISC1 
aggregated. Furthermore, 17β-estradiol causes a redistribution of DISC1, as well as 
PSD-95 and kalrin-7, which form a signalsome with DISC1. Finally, we found that 
chronic, repeated treatment with 17β-estradiol reversed DISC1-induced spine loss in 
neurons, by increasing the number of spines that also were positive for pre- and post-
synaptic protein markers. Taken together, our data indicate that estrogens can restore 
lost excitatory synapses caused by altered DISC1 expression, potentially through the 
bi-directional trafficking of DISC1 and its interacting partners.  
Recent clinical studies have demonstrated that adjunct treatment with 17β-
estradiol and estrogen-based compounds ameliorate positive, negative and cognitive 
symptoms experienced by patients diagnosed with schizophrenia or depression29-34. 
Recent in silico-based studies have also suggested that estrogen-based compounds 
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many confer beneficial effects in SCZ and MDD51, 52. This includes identification of 
selective estrogen receptor modulators as potential repurposable drugs targets for the 
treatment of MDD51. Utilizing an expression-based drug screen on neural progenitor 
cells derived from induced pluripotent stem cells (iPSCs), generated schizophrenic 
individuals the estrogenic compound estriol was found to reverse the transcriptional 
signature associated with SCZ52. Together, these clinical and in silico-based studies 
provide supporting evidence for a potential beneficial role of estrogens in the treatment 
of MDD and SCZ. 
Despite these lines of evidence, the exact molecular and cellular mechanisms 
by which estrogens exert these beneficial effects are not well understood. The 
beneficial effects of 17β-estradiol in disorders such as SCZ and MDD have been 
proposed to occur through the modulation of monoamine transmitter systems such as 
dopamine and 5-HT, or via an anti-inflammatory mechanism30, 33, 36, 53. However, 
increasing evidence suggests that the beneficial effects of 17β-estradiol may also be 
in part conferred through the modulation of glutamatergic signaling27, 35, 36. This is 
supported by animal studies which show that 17β-estradiol enhances performance on 
a number of cognitive tasks, including attention and learning and memory tasks in 
healthy animals27, 28, 54 as well as models of psychosis30, 55-57. Importantly, it is the 
ability of 17β-estradiol to modulate both glutamatergic and GABAergic systems that 
underlies these enhancing effects45, 48, 58-61. This supports the rationale for examining 
whether 17β-estradiol could regulate excitatory synapses in a disease-relevant cellular 
model.  
It is important to consider the use of DISC1 as the mediator of cellular pathology 
in our study. DISC1 had emerged as a candidate risk factor for major mental illnesses, 
including SCZ, autism spectrum disorder, bipolar disorder and MDD15. While DISC1 
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may not directly contribute to the etiology of these disorders15, 19, 20, it has been argued 
that DISC1-based cellular systems are useful in understanding cellular mechanisms 
relevant for neuropsychiatric disorders13, and in exploring potential therapeutic 
agents37. Taking advantage of the ability of DISC1 to induce spine loss, data presented 
in this study provides evidence that 17β-estradiol is capable of increase glutamatergic 
synapse number in a disease-relevant cellular model. Collectively, these data indicate 
that the beneficial effects of estrogens could be driven in part by the regulation of 
glutamatergic synapses. It should be noted, however, that these results do not negate 
the possibility that 17β-estradiol also modulates multiple other systems, and this also 
contributes to its beneficial effects in SCZ and MDD. 
It is of note that in our study overexpression of both full length DISC1 or 
DISC1ΔCT had similar effects to reduce dendritic spine density. DISC1 has been 
shown to regulate spine and synapse morphology and density through its interacting 
partners13, 18, 21, 41. Therefore, there are multiple mechanisms by which DISC1 could 
exert its effects on synapses. For example, DISC1 regulates kalirin-7’s GEF activity 
for Rac1, by modulating the interaction of this protein with PSD-9521. Overexpression 
of DISC1 increases the interaction between kalirin-7 and PSD-95, resulting in a 
decrease activation of Rac121. DISC1 also interacts and regulates the activity of the 
synaptic protein TNIK. Regulation of TNIK activity by DISC1 is required for the correct 
composition of synaptic proteins at synapses and synaptic number41. Several studies 
have shown that expression of mutant DISC1 lacking the C-terminal domain results in 
a loss of dendritic spines in vivo and in vitro indicating a critical role for the C-terminal 
portion of DISC1 in maintenance of spine density22, 23, 26. A recent study using a 
transgenic animal that expresses a C-terminal fragment of DISC1 in an inducible 
manner, demonstrated that a time-dependent loss of dendritic spine density25. As 
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overexpression of the C-terminal fragment is predicted to reduce the ability of DISC1 
to interact with binding partners such as NDEL1, this study provides further evidence 
that the C-terminal and its binding partners are critical for the maintenance and 
formation of dendritic spines. However, it is also interesting to note that insoluble 
DISC1, caused by overexpression of DISC1, is less able to bind to interacting partners 
such as NDEL139, highlighting functional implications of aggregate formation. In our 
primary neuronal cultures, both DISC1 and DISC1ΔCT constructs formed large 
clusters, or aggregates, along dendrites, similar to previous reports39, 46. Thus, it is 
possible that aggregation of DISC1 or DISC1ΔCT disrupts the interactome of this 
protein, and therefore negatively impacts the maintenance of dendritic spines. 
Interestingly, our data indicates that concurrent with a return of spine density to basal 
levels, 17β-estradiol also reduces the extent to which DISC1 forms aggregates. While 
a direct link between DISC1 clustering and spine deficits has not been established, it 
will be interesting in future studies to ascertain whether these are two separate events, 
or whether 17β-estradiol’s ability to restore spine density to basal levels is also 
connected to its ability to reduced DISC1 clustering. 
In support of such an idea, we show that 17β-estradiol is capable of altering the 
distribution of endogenous DISC1 as well. Interestingly, our data indicates 17β-
estradiol reduced the synaptic content of endogenous DISC1. This is consistent with 
previous data indicating that endogenous DISC1 acts to limit spine formation21. 
Activity-dependent signaling reduces the extent to which DISC1 interacts with PSD-
95/kalirin-7 which in turns allows for an increase in spine size and number21, 37. 
Consistent with this model, we show that 17β-estradiol caused the bi-directional 
redistribution of the DISC1/PSD-95/kalirin-7 signalsome. Whereas the presence of 
endogenous DISC1 at synapses is reduced following 17β-estradiol treatment, both 
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PSD-95 and kalirin-7 are increased at synapses. This is consistent with our previous 
data showing that PSD-95 is targeted to nascent spines formed by 17β-estradiol48. An 
increased presence of kalirin-7 at synapses would also be consistent with an increase 
in spine formation. Indeed, we have previously shown that the synaptic localization of 
kaliirn-7 is important for both spine maintenance and formation62. As PSD-95 is 
required for correct kalrin-7 regulation of dendritic spines, the observed increased co-
localized PSD-95/kalirin-7 puncta would indicate that this complex may contribute to 
the formation of nascent spines. Therefore, in this model, 17β-estradiol acts to release 
the complex between DISC1 and PSD-95/kalirin-7, in order to allow it to engage with 
the machinery required for spine formation. 
The data presented in this study support a role for estrogenic-modulation of 
dendritic spines as a potential cellular mechanism by which its beneficial effects in 
SCZ and MDD may occur. Owing to the link between estrogenic regulation of spines 
with improvement in cognitive function, especially in learning and memory45, 60, 61, as 
well as emerging data that estrogen-based compounds improve attention and working 
memory in male and female SCZ patients29, 31, 33, 36, it is intriguing to suggest that this 
is part of the mechanisms that underlies the beneficial actions of estrogens. It is likely 
that the regulation of spines by 17β-estradiol is only part of the mechanism underlying 
its beneficial actions. Critically, future studies using genetic models of disease or 
patient iPSC models should allow for a more faithful recapitulation of both the cellular 
and complex genetic architecture associated with these disorders. We have shown 
that neurons derived from iPSC lines are responsive to estrogens63, demonstrating 
that this system could be useful for the study of estrogen-based compounds. 
Nevertheless, the data in this study support further investigations into estrogenic 
24 
 
modulation of glutamatergic signaling and highlights this mechanism as having 
relevance for the therapeutic potential of estrogens in SCZ and MDD. 
In conclusion, our data indicates that estrogens can restore lost excitatory 
synapses caused by altered DISC1 expression, potentially through the bi-directional 
trafficking of DISC1 and its interacting partners. These data highlight the possibility 
that estrogens exert their beneficial effects in SCZ and MDD, in part by modulating 
excitatory synaptic number. 
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Figure Legends: 
 
Figure 1. Acute 17β-estradiol (E2) treatment increases dendritic spine linear 
density in neurons overexpressing HA-DISC1 or HA-DISC1ΔCT and reduces 
36 
 
DISC1 aggregation. (A) Representative images of cortical neurons (DIV 26) 
transfected with GFP alone (control), GFP + HA-DISC1 or GFP + HA-DISC1ΔCT and 
treated with vehicle (Veh) or 17β-estradiol (E2) or not. (B) Quantification of spine linear 
density. Treatment of control cells with 17β-estradiol resulted in an increase in spine 
number. Overexpression of HA-DISC1 or HA-DISC1ΔCT caused a significant 
reduction in spine linear density. Treatment with 17β-estradiol increased spine density 
in HA-DISC1 HA-DISC1ΔCT expressing cells to a level not statistically different to 
vehicle control cells (dendritic spine linear density/10 µm): control, 5.8±0.21; control + 
17β-estradiol, 7.27±0.44; HA-DISC1, 3.9±0.2; HA-DISC1 + 17β-estradiol, 5.22±0.34; 
HA-DISC1ΔCT, 3.4±0.36; HA-DISC1ΔCT + 17β-estradiol, 5.5±0.37). (C) 
Representative images of DIV 26 cortical neurons expressing either HA-DISC1 or HA-
DISC1ΔCT were treated with vehicle or 17β-estradiol for 30 minutes. Pseudo-color 
scheme is used to highlight regions where DISC1 clustering is occurring. Green arrow 
heads indicate DISC1 clusters in each condition. (D) Quantification of DISC1 
clustering; both HA-DISC1 or HA-DISC1ΔCT formed large clusters along dendrites. 
Treatment with 17β-estradiol reduced DISC1 clustering in neurons expressing either 
HA-DISC1 or HA-DISC1ΔCT. Scale bar = 5 µm.  
 
Figure 2. Acute 17β-estradiol (E2) treatment restores dendritic spine density 
following long term DISC1 knockdown. (A and B) Western blot of hEK293 cells 
expressing HA-DISC1 in presence of control shRNA vector (pGSuper) or DISC1-
shRNA (A). Quantification of HA-DISC1 expression (B), normalized to β-actin 
demonstrates that DISC1_shRNA effectivity knockdown exogenous DISC1 as 
previously reported.  (C) Representative images of cortical neurons expressing control 
shRNA vector (pGSuper) or shRNA against DISC1 (DISC1_shRNA) for 7 days; 
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neurons were treated with vehicle (Veh) or E2 (10 nM) for 30 minutes. (D) 
Quantification of dendritic spine linear density (per 10 µm). As recently reported, 
expression of DISC1_shRNA for 7 days results in a reduction in spine linear density; 
as expected 30 minute E2 increases spine density in Control neurons; intriguingly, E2 
treatment for 30 min increased spine density in DISC1_shRNA expressing cells to 
Control neuron levels (dendritic spine linear density (per 10 µm): control, 5.1±0.3; 
control + 17β-estradiol, 7.25±0.49; DISC1_shRNA, 3.4±0.35; DISC1_shRNA + 17β-
estradiol, 4.95±0.27). Scale bar = 5 µm. 
 
Figure 3. Bi-directional redistribution of DISC1/PSD-95/kalirin-7 signalosome by 
17β-estradiol (E2). (A) Whole cell lysate, crude synaptosome (P2) and cytosol (S2) 
fractions of cortical neurons treated with 17β-estradiol (E2) for 0 or 30 minutes 
analyzed by Western blotting for expression of DISC1, PSD-95 or kalirin-7; β-actin 
was used as a loading control. Arrows indicate DISC1 and kalirin isoforms measured 
in analysis. E2 has no effect on overall expression levels of DISC1, kalirin-7 or PSD-
95 within 30 minutes as seen in whole cell lysate. Treatment with E2 causes a 
reduction of DISC1 in crude synaptosome fraction and an increase in cytosolic 
fraction. E2 treatment resulted in an enrichment of kalirin-7 and PSD-95 within crude 
synaptosome fraction and concurrent reduction in cytosolic fraction. (B) Quantification 
of DISC1, PSD-95 and kalirin-7 enrichment in crude synaptosome and cytosol 
fractions. (C) GFP-expressing and DISC1 (440) stained cortical neurons treated with 
E2 for 30 minutes or not. Quantification of DISC1 cluster intensity within spines reveals 
a reduction in intensity within spines after E2 treatment. (D) Cortical neurons (DIV 25) 
fixed before and after treatment with E2 and immunostaining for kalirin-7 and PSD-95. 
E2 treatment (30 mins) increases kalirin-7 puncta density (black bars). Assessment of 
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number of kalirin-7/PSD-95 co-localized puncta revealed and increase in kalirin-7 and 
PSD-95 positive puncta (red bars), indicating that kalirin-7 is being targeted to 
synapses (*, p  < 0.01 (corrected for multiple comparisons) Student t-test; n = 12-15 
cells per condition from 3 independent cultures). (E) GFP-expressing and kalirin-7 
stained cortical neurons treated with E2 for 30 minutes or not. Quantification of kalirin-
7 cluster intensity within spines reveals an enrichment within spines following 
treatment (*, p < 0.05, Student t-test; n = 270-341 spines from 6 cells per condition 
from 3 independent cultures). Scale bar = 5 µm. 
 
Figure 4. Chronic repeated treatment with 17β-estradiol (E2) rescues DISC1-
induced spine deficits and reduces DISC1 aggregation. (A) Schematic of chronic 
repeated 17β-estradiol (E2) treatment of either control or HA-DISC1ΔCT expressing 
neurons. Cortical neurons were transfected with GFP alone (control) or GFP and HA-
DISC1ΔCT at DIV 17. Cells were treated daily with vehicle or 10 nM 17β-estradiol on 
DIV17-20. Neurons were fixed on DIV21. (B) Representative confocal images of 
DIV25 cortical neurons treated as in A. (C) Quantification of dendritic spine linear 
density. Chronic repeated treatment with 17β-estradiol increased in spine density in 
control cells. Ectopic expression of HA-DISC1ΔCT caused a significant reduction in 
spine linear density. Chronic repeated treatment with 17β-estradiol increased spine 
density in HA-DISC1ΔCT expressing cells to a level not statistically different to vehicle 
control cells. (D) Representative images of DIV 25 cortical neurons expressing either 
GFP alone or HA-DISC1ΔCT were treated with vehicle or 17β-estradiol daily between 
DIV17 and 24. Pseudo-color scheme is used to highlight regions where DISC1ΔCT 
clustering is occurring. (E) Quantification of DISC1 clustering. Chronic repeated 
treatment with 17β-estradiol reduced HA-DISC1ΔCT clustering. Scale bar = 5 µm. 
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Figure 5. Repeated treatment with 17β-estradiol (E2) increases the number of 
dendritic spines positive for pre- and post-synaptic markers. (A) Representative 
confocal images of DIV25 cortical neurons triple immunostained for GFP, PSD-95 
(post-synaptic protein) and bassoon (pre-synaptic protein). Neurons were treated as 
outlined in Figure 4A. (B) Quantification of linear density of total spine density (open 
bars) or spines containing PSD-95 (grey and blue solid/hatched bars). Chronic 
repeated treatment with 17β-estradiol increased the number of spines positive for 
PSD-95 in control and HA-DISC1ΔCT expressing neurons. (C) Quantification of linear 
density of total spine density (open bars) or spines with overlap for bassoon (light grey 
and light magenta solid/hatched bars). Chronic repeated treatment with 17β-estradiol 
increased the number of spines overlapping with bassoon in control and HA-
DISC1ΔCT expressing neurons. (D) Quantification of linear density of total spine 
density (open bars) or spines containing PSD-95 and that overlapped with bassoon 
(dark grey and teal solid/hatched bars). Chronic repeated treatment with 17β-estradiol 
increased the number of spines positive for PSD-95 and bassoon in control and HA-
DISC1ΔCT expressing neurons. Scale bar = 5 µm. 
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Supplemental Material 
 
Supplemental Figures 
  
 
 
Supplemental Figure 1. Full length and C-terminal truncated DISC1 induces 
spine loss in primary cortical neurons. 
(A) Representative images of cortical neurons (DIV 26) transfected with GFP alone, 
GFP + HA-DISC1 or GFP + HA-DISC1ΔCT. (B) Quantification of spine linear density. 
Overexpression of HA-DISC1 causes a reduction of spine density as previously 
reported; exogenous expression of DISC1ΔCT also causes a reduction in spine linear 
density (dendritic spine linear density/10 µm): control, 6.3±0.6; HA-DISC1, 2.87±0.42; 
HA-DISC1ΔCT, 2.54±0.34). Scale bar = 5 μm. 
 
 
  
  
Supplemental Figure 2. Full length and C-terminal truncated DISC1 aggregates 
within dendrites of cortical neurons.  
Representative images of cortical neurons (DIV 26) transfected with GFP alone, GFP 
+ HA-DISC1 or GFP + HA-DISC1ΔCT. (A) Endogenous DISC1 could be observed in 
discreet punctate strictures within dendrites and juxtaposed to dendrites. In 
comparison, both wildtype and ΔCT forms of DISC1 were found to aggregate within 
dendrites. Scale bar = 5 μm.  
 
 
 
  
  
 
 
Supplemental Figure 3. 17β-estradiol increases dendritic spine density in a 
dose-response manner. Primary cortical neuron expressing GFP were treated with 
17β-estradiol at range of concentrations for 30 minutes. Following fixation and 
immunocytochemistry, dendritic spine linear density was assessed. Treatment with 1 
or 10 nM 17β-estradiol increased spine linear density significantly; 10 or 100 pM as 
well as 100 nM 17β-estradiol did not alter spine density significantly compared to 
vehicle treated control neurons. Scale bar = 5 µm. 
  
  
Supplemental Figure 4. Estradiol induced trafficking of DISC1 and kalirin-7. (A) 
High magnification of areas highlighted by yellow dashed boxes in Figure 3C; line 
scan of DISC1 staining within spine heads further demonstrates a redistribution of 
DISC1 from spines to dendritic shaft after E2 treatment. (B) High magnification of 
areas highlighted by yellow dashed boxes in Figure 3E; line scan of kalirin-7 
distribution within spine heads reveals an enrichment of kalirin-7 within spine heads 
after E2 treatment. Scale bar = 1 µm. 
 
